These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22416427)

  • 1. [The detection of minimal residual disease in patients with chronic B-cell lymphatic leukemia using patient-specified polymerase chain reaction].
    Sidorova IuV; Sorokina TV; Biderman BV; Nikulina EE; Kisilichina DG; Naumova EV; Pochtar' ME; Lugovskaia SA; Ivanova VL; Kovaleva LG; Ptushkin VV; Nikitin EA; Sudarikov AB
    Klin Lab Diagn; 2011 Dec; (12):22-4, 33-5. PubMed ID: 22416427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation.
    Farina L; Carniti C; Dodero A; Vendramin A; Raganato A; Spina F; Patriarca F; Narni F; Benedetti F; Olivieri A; Corradini P
    Haematologica; 2009 May; 94(5):654-62. PubMed ID: 19377072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
    Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
    Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
    Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
    Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia.
    Pfitzner T; Engert A; Wittor H; Schinköthe T; Oberhäuser F; Schulz H; Diehl V; Barth S
    Leukemia; 2000 Apr; 14(4):754-66. PubMed ID: 10764166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
    Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
    Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements.
    Vuillier F; Claisse JF; Vandenvelde C; Travade P; Magnac C; Chevret S; Desablens B; Binet JL; Dighiero G
    Leuk Lymphoma; 1992 Jun; 7(3):195-204. PubMed ID: 1282428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia.
    Maloum K; Sutton L; Baudet S; Laurent C; Bonnemye P; Magnac C; Merle-Béral H
    Br J Haematol; 2002 Dec; 119(4):970-5. PubMed ID: 12472575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
    Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
    Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia.
    Peková S; Marková J; Pajer P; Dvorák M; Cetkovský P; Schwarz J
    Mol Diagn; 2005; 9(1):23-34. PubMed ID: 16035732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia.
    Schultze JL; Donovan JW; Gribben JG
    J Mol Med (Berl); 1999 Feb; 77(2):259-65. PubMed ID: 10023779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL).
    Magnac C; Sutton L; Cazin B; Laurent C; Binet JL; Merle-Béral H; Dighiero G; Maloum K
    Hematol Cell Ther; 1999 Feb; 41(1):13-8. PubMed ID: 10193641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The prognostic value of evaluation of minimal residual disease using technique of flow cytofluorometry during application of therapy of chronic lymphatic leukemia].
    Kisilichina DG; Lugovskaia CA; Naumova EV; Pochtar' ME; Nikitin EA; Dolgov VV
    Klin Lab Diagn; 2014 Nov; 59(11):26-30. PubMed ID: 25850241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
    Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.
    Arons E; Margulies I; Sorbara L; Raffeld M; Stetler-Stevenson M; Pastan I; Kreitman RJ
    Clin Cancer Res; 2006 May; 12(9):2804-11. PubMed ID: 16675574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease in B-lymphoproliferative disorders by PCR detection of immunoglobulin heavy chain gene recombination.
    Petroni D; Saglio G
    Scand J Clin Lab Invest; 1997 Oct; 57(6):541-7. PubMed ID: 9350074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance.
    Della Starza I; Cavalli M; Del Giudice I; Barbero D; Mantoan B; Genuardi E; Urbano M; Mannu C; Gazzola A; Ciabatti E; Guarini A; Foà R; Galimberti S; Piccaluga P; Gaidano G; Ladetto M; Monitillo L
    Hematol Oncol; 2014 Sep; 32(3):133-8. PubMed ID: 24254547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
    Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
    Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.